Topiramate
150 mg · Capsule, Extended Release
- Prescription only
- Active substance
- Topiramate
- Made by
- Zydus Lifesciences Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
This information is not included in the verified source. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Topiramate). It describes the substance, not this exact product.
The precise mechanisms by which topiramate exerts its anticonvulsant and preventive migraine effects are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate's efficacy for epilepsy and the preventive treatment of migraine.
Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly isozymes II and IV.
Metabolism and Excretion Topiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose).
The bioavailability of topiramate is not affected by food.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-04
Safety of the active substance
From the US prescribing label for the same active substance (Topiramate). It describes the substance, not this exact product.
- Topiramate is contraindicated in patients with a history of hypersensitivity reaction to topiramate, Topiramate tablets, or any of the inactive ingredients of Topiramate tablet.
- Anaphylaxis and angioedema have occurred [see Warnings and Precautions (5.13)].
- History of hypersensitivity reaction to topiramate, topiramate tablets, or any of the inactive ingredients of topiramate tablet.
The most common adverse reactions in the controlled clinical trial (Study 1) that occurred in adults in the 400 mg/day topiramate tablets group and at an incidence higher (≥10 %) than in the 50 mg/day group were: paresthesia, weight loss and anorexia (see Table 5).
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
Details
| Made by | Zydus Lifesciences Limited |
|---|---|
| Active substance | Topiramate |
| Strength | 150 mg |
| Form | Capsule, Extended Release |
| Route | Oral |
| Packs | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE · 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE |
| NDC | 70771-1659 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
211 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Tablet, Film Coated82 products
- Capsule, Extended Release59 products
150 mg7
150 mg · 7 companies
- Tablet48 products
- Capsule11 products
Show all forms · 6 forms
- Capsule, Coated Pellets9 products
15 mg3
50 mg2
50 mg · 2 companies
- Solution2 products
25 mg/mL2
25 mg/mL · 2 companies
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.